| Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis JU Scher, A Sczesnak, RS Longman, N Segata, C Ubeda, C Bielski, ... elife 2, e01202, 2013 | 1876 | 2013 |
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease JU Scher, C Ubeda, A Artacho, M Attur, S Isaac, SM Reddy, S Marmon, ... Arthritis & rheumatology 67 (1), 128-139, 2015 | 810 | 2015 |
| 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis JA Singh, G Guyatt, A Ogdie, DD Gladman, C Deal, A Deodhar, ... Journal of Psoriasis and Psoriatic Arthritis 4 (1), 31-58, 2019 | 718 | 2019 |
| Periodontal disease and the oral microbiota in new‐onset rheumatoid arthritis JU Scher, C Ubeda, M Equinda, R Khanin, Y Buischi, A Viale, L Lipuma, ... Arthritis & Rheumatism 64 (10), 3083-3094, 2012 | 560 | 2012 |
| The microbiome and rheumatoid arthritis JU Scher, SB Abramson Nature reviews rheumatology 7 (10), 569-578, 2011 | 534 | 2011 |
| The role of the gut microbiome in systemic inflammatory disease JC Clemente, J Manasson, JU Scher Bmj 360, 2018 | 493 | 2018 |
| Covid-19 in immune-mediated inflammatory diseases—case series from New York R Haberman, J Axelrad, A Chen, R Castillo, D Yan, P Izmirly, A Neimann, ... New England Journal of Medicine 383 (1), 85-88, 2020 | 453 | 2020 |
| 15d-PGJ2: the anti-inflammatory prostaglandin? JU Scher, MH Pillinger Clinical immunology 114 (2), 100-109, 2005 | 421 | 2005 |
| The anti-inflammatory effects of prostaglandins JU Scher, MH Pillinger Journal of Investigative Medicine 57 (6), 703-708, 2009 | 303 | 2009 |
| Short-and long-term effects of oral vancomycin on the human intestinal microbiota S Isaac, JU Scher, A Djukovic, N Jiménez, DR Littman, SB Abramson, ... Journal of Antimicrobial Chemotherapy 72 (1), 128-136, 2016 | 291 | 2016 |
| Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition JU Scher, A Ogdie, JF Merola, C Ritchlin Nature Reviews Rheumatology 15 (3), 153-166, 2019 | 287 | 2019 |
| Microbiome in inflammatory arthritis and human rheumatic diseases JU Scher, DR Littman, SB Abramson Arthritis & rheumatology 68 (1), 35-45, 2016 | 282 | 2016 |
| Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease RH Haberman, R Herati, D Simon, M Samanovic, RB Blank, M Tuen, ... Annals of the rheumatic diseases 80 (10), 1339-1344, 2021 | 269 | 2021 |
| Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity SB Brusca, SB Abramson, JU Scher Current opinion in rheumatology 26 (1), 101-107, 2014 | 269 | 2014 |
| Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism A Zanin-Zhorov, JM Weiss, MS Nyuydzefe, W Chen, JU Scher, R Mo, ... Proceedings of the National Academy of Sciences 111 (47), 16814-16819, 2014 | 225 | 2014 |
| The lung microbiota in early rheumatoid arthritis and autoimmunity JU Scher, V Joshua, A Artacho, S Abdollahi-Roodsaz, J Öckinger, ... Microbiome 4, 1-10, 2016 | 186 | 2016 |
| Psoriatic arthritis O FitzGerald, A Ogdie, V Chandran, LC Coates, A Kavanaugh, W Tillett, ... Nature reviews Disease primers 7 (1), 59, 2021 | 161 | 2021 |
| The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions S Abdollahi-Roodsaz, SB Abramson, JU Scher Nature Reviews Rheumatology 12 (8), 446-455, 2016 | 143 | 2016 |
| Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial CT Ritchlin, A Kavanaugh, JF Merola, G Schett, JU Scher, RB Warren, ... The Lancet 395 (10222), 427-440, 2020 | 134 | 2020 |
| Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis AI Catrina, KD Deane, JU Scher Rheumatology 55 (3), 391-402, 2016 | 131 | 2016 |
